← All trials
NCT05682131
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2022
- Primary completion
- Sep 27, 2027
- Completion date
- Sep 27, 2030
- First posted
- Jan 12, 2023
- Last posted
- Jan 12, 2023
- Enrollment
- 210
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Hacettepe UniversityCollaborator
- Shantou UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Hainan People's HospitalCollaborator
- Huizhou People's Central HospitalCollaborator
- Central South UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Zhongshan Bo Ai HospitalCollaborator
- Xiamen UniversityCollaborator
- Southern Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.